Anthrax (Bacillus anthracis)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
Anthrax is a serious infection caused by the bacterium Bacillus anthracis that mainly affects the skin, lungs, and digestive system. It can enter the body through cuts in the skin, inhalation, or ingestion, leading to different forms of the disease. The most common form is cutaneous anthrax, which causes a painless sore with a black center. Inhalation anthrax affects the lungs and can cause severe breathing problems. Gastrointestinal anthrax affects the digestive tract and can cause severe abdominal pain and vomiting. The infection can spread quickly and become life-threatening if not treated promptly. Anthrax spores can survive in the environment for a long time, making it a concern for both natural outbreaks and bioterrorism.
Clinical Definition
Anthrax is a toxin-mediated infection classically caused by the gram-positive, spore-forming Bacillus anthracis. Entry can be cutaneous, inhalational, gastrointestinal or injection-associated. Cutaneous disease classically causes a painless eschar with edema; inhalation disease involves thoracic lymph nodes and hemorrhagic mediastinitis, often with pleural effusions. Any form can disseminate, causing shock or hemorrhagic meningitis.
Inciting Event
Direct contact with spores through skin abrasions or mucous membranes initiates cutaneous anthrax.
Inhalation of aerosolized spores triggers inhalational anthrax with pulmonary involvement.
Ingestion of contaminated meat causes gastrointestinal anthrax.
Injection of contaminated drugs can cause injectional anthrax in intravenous drug users.
Latency Period
Cutaneous anthrax incubation typically ranges from 1 to 7 days after exposure.
Inhalational anthrax latency is usually 1 to 6 days but can be up to 60 days due to spore dormancy.
Gastrointestinal anthrax symptoms develop within 1 to 7 days post ingestion.
Injectional anthrax onset occurs within days to weeks after drug injection.
Diagnostic Delay
Nonspecific early symptoms such as fever and malaise mimic common infections, delaying diagnosis.
Lack of clinical suspicion in non-endemic areas leads to misdiagnosis.
Initial skin lesions resembling insect bites or cellulitis cause delayed recognition of cutaneous anthrax.
Limited access to specialized microbiologic testing for B. anthracis spores and toxin detection.
Clinical Presentation
Signs & Symptoms
Painless skin ulcer with a central black eschar and surrounding non-pitting edema in cutaneous anthrax.
Fever, malaise or headache can indicate systemic involvement, but may be absent in localized cutaneous disease.
Dyspnea, chest pain, and cough in inhalational anthrax due to hemorrhagic mediastinitis.
Severe gastrointestinal symptoms including nausea, vomiting, abdominal pain, and bloody diarrhea in gastrointestinal anthrax.
Rapid progression to septic shock in systemic anthrax infection.
History of Present Illness
Cutaneous anthrax begins with a painless papule that rapidly progresses to a vesicle and then a characteristic black eschar with surrounding edema.
Inhalational anthrax presents initially with nonspecific flu-like symptoms followed by severe respiratory distress and mediastinal widening on imaging.
Gastrointestinal anthrax manifests as severe abdominal pain, vomiting, and bloody diarrhea after ingestion of contaminated meat.
Injectional anthrax presents with severe soft tissue infection, extensive edema, and systemic toxicity without the classic eschar.
Past Medical History
Previous occupational exposure to animal products or travel to endemic areas increases risk.
History of skin trauma or wounds may predispose to cutaneous infection.
Immunocompromised states can worsen disease severity and complicate treatment.
Lack of prior anthrax vaccination in high-risk individuals is relevant.
Family History
[]
Physical Exam Findings
Painless ulcer with a black eschar surrounded by significant edema in cutaneous anthrax.
In inhalation disease, respiratory distress or abnormal breath sounds may be present. Mediastinal widening is a chest-imaging finding, not something established by physical examination.
Tachycardia and hypotension indicating systemic toxicity in severe anthrax infection.
Pleural effusion signs such as decreased breath sounds in inhalational anthrax.
Lymphadenopathy near the site of infection in cutaneous anthrax.
Diagnostic Workup
Diagnostic Criteria
Suspect anthrax from exposure and syndrome, then coordinate urgent laboratory/public-health testing with culture, PCR and other validated tests. A large gram-positive rod on microscopy is suggestive, not definitive; spores are generally not seen in clinical material. Collect appropriate specimens when feasible without delaying antibiotics. Assess systemic cases for meningitis.
Pathophysiology
Key Mechanisms
Spore inhalation or cutaneous entry of Bacillus anthracis leads to germination and bacterial proliferation.
Protective antigen (PA) delivers toxin enzymes into host cells: PA plus edema factor forms edema toxin; PA plus lethal factor forms lethal toxin. PA is not itself the catalytic enzyme.
Edema factor is a calmodulin-dependent adenylate cyclase that raises intracellular cAMP, promoting edema and disrupting host defenses.
Lethal factor is a zinc-dependent protease that cleaves MAP kinase kinases, disrupting cell signaling and contributing to tissue injury, vascular dysfunction and shock; its effects are not simply universal macrophage apoptosis.
The antiphagocytic capsule consists of poly-D-glutamic acid, a polypeptide rather than the polysaccharide found in most bacterial capsules.
| Involvement | Details |
|---|---|
| Organs | Lymph nodes serve as sites of bacterial replication and immune response initiation in systemic anthrax. |
Thoracic lymph nodes, mediastinum and pleura are central to inhalation anthrax; pulmonary involvement and effusions contribute to respiratory failure. | |
Skin is the organ involved in cutaneous anthrax, presenting with characteristic lesions. | |
| Tissues | Skin is the primary site of entry in cutaneous anthrax, where characteristic black eschar forms. |
Lymphatic tissue is involved as spores germinate and bacteria multiply, leading to lymphadenopathy. | |
Mediastinal lymphatic tissue and pleura can develop hemorrhagic inflammation and effusions; mediastinitis is not inflammation confined to lung parenchyma. | |
| Cells | Macrophages phagocytose Bacillus anthracis spores and transport them to lymph nodes, initiating infection. |
Neutrophils are recruited to sites of infection to kill bacteria but may be overwhelmed by anthrax toxins. | |
Dendritic cells present anthrax antigens to activate adaptive immune responses. | |
| Chemical Mediators | Anthrax lethal toxin disrupts immune cell signaling causing cell death and immune evasion. |
Protective antigen facilitates entry of lethal and edema toxins into host cells, critical for virulence. | |
Edema toxin increases intracellular cAMP causing local edema and immune suppression. |
Treatments
Pharmacological Treatments
Ciprofloxacin
- Mechanism:
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in Bacillus anthracis.
- Side effects:
Tendon rupture
Gastrointestinal upset
Photosensitivity
- Clinical role:
Option for localized cutaneous disease or PEP; in systemic disease use a guideline-directed combination regimen, with meningitis assessment.
Doxycycline
- Mechanism:
Binds to the 30S ribosomal subunit, inhibiting protein synthesis in Bacillus anthracis.
- Side effects:
Photosensitivity
Gastrointestinal upset
Dental effects are a tetracycline-class concern, but doxycycline has a different risk profile; age alone must not prevent indicated anthrax therapy.
- Clinical role:
Option for cutaneous disease/PEP and a protein-synthesis-inhibiting component of selected systemic regimens; not systemic monotherapy.
Raxibacumab
- Mechanism:
Monoclonal antibody that neutralizes anthrax toxin protective antigen, preventing toxin entry into host cells.
- Side effects:
Infusion reactions
Hypersensitivity reactions
- Clinical role:
Adjunctive antitoxin with antibiotics, particularly for noncutaneous systemic anthrax; obtain specialist/public-health consultation.
Anthrax vaccine (AVA)
- Mechanism:
Stimulates active immunity by inducing antibodies against anthrax protective antigen.
- Side effects:
Injection site reactions
Mild fever
Fatigue
- Clinical role:
Prevention, including appropriate exposure prophylaxis with antibiotics; does not treat established disease.
Non-pharmacological Treatments
Do not routinely excise or debride an uncomplicated cutaneous anthrax eschar. Injection-associated deep necrosis or compartment syndrome may require specialist surgery; distinguish these settings.
Provide hemodynamic and respiratory support; specialist drainage of significant pleural effusions or ascites may be needed in systemic disease.
Use standard precautions; add contact precautions for uncontained copious lesion drainage. Inhalation anthrax does not require airborne isolation for person-to-person spread. Environmental spore exposure requires separate public-health precautions.
Prevention
Pharmacological Prevention
Anthrax vaccine is used for selected high-risk groups and appropriate PEP. FDA-approved Cyfendus, an adjuvanted vaccine, is a PEP option for ages 18-65 with antibiotics; products and schedules differ.
After credible exposure, PEP depends on route, age, immune status and vaccination. Aerosol exposure often requires prolonged antibiotics, commonly 60 days; shorter schedules apply to some vaccinated healthy adults. Not every exposure requires the same course.
Antitoxin primarily supports treatment; public-health guidance may use it for PEP when appropriate antibiotics are unavailable. It is not routine outbreak prophylaxis for everyone.
Non-pharmacological Prevention
Avoidance of exposure to contaminated animal products and soil in endemic areas.
Use of personal protective equipment (PPE) including gloves and masks when handling potentially infected materials.
Proper disposal and incineration of animal carcasses to prevent spore dissemination.
Environmental decontamination of areas exposed to anthrax spores.
Education and training of at-risk workers on anthrax transmission and early symptom recognition.
Outcome & Complications
Complications
Septic shock due to systemic dissemination of Bacillus anthracis and toxin release.
Hemorrhagic mediastinitis causing respiratory failure in inhalational anthrax.
Meningitis secondary to hematogenous spread of anthrax.
Airway obstruction from massive edema in oropharyngeal or inhalational anthrax.
Death if untreated or in severe systemic cases.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Anthrax (Bacillus anthracis) versus Cutaneous Tularemia
Anthrax (Bacillus anthracis) | Cutaneous Tularemia |
|---|---|
Exposure to contaminated animal products or soil | Contact with rabbits or ticks in endemic areas |
Painless black eschar with extensive surrounding edema | Ulceroglandular lesion with granulomatous inflammation |
Positive culture or PCR for Bacillus anthracis | Positive serology or culture for Francisella tularensis |
Anthrax (Bacillus anthracis) versus Necrotizing Cellulitis (e.g., Staphylococcus aureus)
Anthrax (Bacillus anthracis) | Necrotizing Cellulitis (e.g., Staphylococcus aureus) |
|---|---|
Painless black eschar with marked non-pitting edema | Rapidly progressive painful erythema with systemic toxicity |
Edema with minimal neutrophilic infiltration and large gram-positive rods | Suppurative inflammation with neutrophilic infiltration |
Antibiotics treat vegetative bacteria; prolonged PEP addresses later germination. Regimen depends on localized versus systemic disease. | Suspected necrotizing soft-tissue infection requires urgent surgical assessment and broad IV antibiotics, including MRSA coverage; a simple beta-lactam alone may be inadequate. |
Anthrax (Bacillus anthracis) versus Orf Virus Infection
Anthrax (Bacillus anthracis) | Orf Virus Infection |
|---|---|
Exposure to livestock or animal hides contaminated with spores | Direct contact with sheep or goats |
Painless ulcer with black eschar and extensive edema | Single or multiple nodular lesions with viral cytopathic changes |
Culture or PCR positive for Bacillus anthracis | PCR positive for parapoxvirus DNA |
Anthrax (Bacillus anthracis) versus Brown Recluse Spider Bite
Anthrax (Bacillus anthracis) | Brown Recluse Spider Bite |
|---|---|
Exposure to contaminated animal products or soil | A compatible bite in the relevant geographic range supports the diagnosis; an unwitnessed presumed spider bite is not confirmation. |
Painless black eschar with marked non-pitting edema | A bite may initially be painless and later become painful/necrotic; systemic illness is possible but not universal. |
Rapid onset of painless eschar with localized edema | Lesion evolves over days with possible systemic hemolysis |
Anthrax (Bacillus anthracis) versus Ecthyma Gangrenosum
Anthrax (Bacillus anthracis) | Ecthyma Gangrenosum |
|---|---|
Can occur in immunocompetent hosts after spore exposure | Occurs primarily in immunocompromised patients (e.g., neutropenia) |
Black eschar with extensive edema caused by Bacillus anthracis toxin | Necrotic skin lesions with vasculitis caused by Pseudomonas aeruginosa |
Positive culture or PCR for Bacillus anthracis | Positive culture for Pseudomonas aeruginosa |